Zafirlukast Tablet, Film Coated
Product Images NDC 55111-626

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Zafirlukast (NDC 55111-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1

FDA Label Image

Container2

FDA Label Image

Graph (Graph)

This text appears to be describing the mean B2-agonist use in puffs per day and adjusted treatment means in a clinical trial. The treatment means are identified as Placebo, Zafirlukast 20 mg twice daily, and Cromolyn sodium 1600 mcg four times a day. The clinical trial lasted for 14 weeks, and the B2-agonist use was measured over that period, with the results displayed in a graph.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.